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OVERVIEW ON NON-SMALL CELL LUNG CANCER 
Lung cancer represents a major healthcare issue, as it is the third most frequently 
diagnosed malignancy, and the first cause of cancer-related deaths in the United 
States. The high mortality of lung cancer is at least partially related to the fact that 
this cancer is often diagnosed in advanced stage, when only palliative treatments 
are available [1]. Lung cancer is divided into two distinct entities based on 
histology: non-small cell lung cancer (NSCLC) and small cell lung cancer 
(SCLC), the former being the most represented (roughly 80-90% of cases); 
additionally, NSCLC is divided into two further sub-groups: non-squamous 
NSCLC and squamous NSCLC. The rationale for a distinction among different 
histologic sub-groups is that the therapeutic approach may be significantly 
different on the basis of histology, as explained later [2].  
With regards to the therapeutic management of NSCLC, the optimal approach is 
based on the disease stage according to the International Association for the Study 
of Lung Cancer (IASLC) TNM staging system [ 3 ]. Early stage NSCLC is 
typically managed with loco-regional approaches, represented in first place by 
radical surgery (mostly lobectomy, but including more extensive procedures such 
as pneumonectomy or more limited techniques such as segmentectomy), which is 
expected to include a proper hilar and mediastinal lymphadenectomy. After 
surgery, a pathological report showing tumor size > 4 cm or lymph nodal 
involvement identifies those patients for whom adjuvant chemotherapy (4 cycles 
of a platinum-based combination) is associated with a reduction of recurrence risk 
and is therefore indicated [4 ]; additionally, adjuvant mediastinal radiation is 
usually offered to patients with mediastinal lymph nodal involvement (pN2) as 
this approach is described to improve local control and survival in this specific 
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patients’ sub-group [5]. Locally advanced NSCLC (including large tumors or pre-
operative evidence of mediastinal lymph nodal involvement) represents a 
heterogeneous and challenging setting, in which multi-disciplinary assessment is 
advised for each patient, as some cases might be eligible for radical surgery after 
neoadjuvant chemotherapy, while the standard upfront approach for non-
resectable, locally advanced NSCLC is represented by concurrent or sequential 
chemo-radiation. Superior sulcus tumors are a specific and uncommon entity that 
might be managed through a multimodality approach including chemo-radiation 
and surgery, provided that the tumor is potentially resectable in first place [6,7]. 
With regards to advanced or recurrent disease not amenable to loco-regional 
treatments, the approach of choice is systemic therapy, represented by 
chemotherapy, targeted agents, and immune checkpoint inhibitors (the latter will 
be discussed in the following sections).  
Chemotherapy has been for many years the corner-stone for the treatment of 
advanced NSCLC, and the most widely employed first-line regimens include a 
combination of a platinum-derivate (cisplatin or carboplatin) and a third-
generation compound, while second-line and further line regimens usually involve 
the administration of a single-agent such as docetaxel (the standard second-line 
chemotherapy until recently), vinorelbine, or gemcitabine [8]. Notably, histology 
drives the choice of the employed chemotherapeutic regimens and, based on 
efficacy as well as safety data, some combinations have been limited to specific 
histologic sub-groups (e.g.: regimens including a platinum-derivate and 
pemetrexed with subsequent maintenance with single-agent pemetrexed are 
limited to non-squamous histology) [9]. A noteworthy addition to chemotherapy 
(also limited to non-squamous NSCLC) is represented by angiogenesis-disrupting 
agents; such agents include bevacizumab, which inhibits the vascular endothelial 
growth factor (VEGF) and has been employed in addition to platinum-based 
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combinations with benefit in terms of efficacy, and nintedanib, which is a VEGF-
inhibitor as well as a multi-target tyrosine kinase inhibitor (TKI) and has been 
added to docetaxel resulting in survival advantage [10]. 
Targeted agents are compounds directed against specific molecules that are the 
product of genic alterations. The most clinically relevant molecular alterations 
identified so far are the activating mutations of the epidermal growth factor 
receptor (EGFR) gene, the rearrangements of the anaplastic lymphoma kinase 
(ALK) gene and rearrangements of the c-ros oncogene 1 (ROS1) gene. These 
aberrations are typically observed in non-squamous histology and are relatively 
uncommon in the Caucasian population; indeed, EGFR mutations account for 10-
15% of patients, while ALK and ROS1 rearrangements account for approximately 
5% and 1% of patients, respectively [ 11 ]. From a therapeutic perspective, 
antineoplastic agents directed against these mutated targets have generally 
achieved improved outcomes compared to standard chemotherapy. With regards 
to EGFR inhibitors, several TKIs are currently available in clinical practice, 
ranging from first-generation TKIs (erlotinib and gefitinib) to second-generation 
inhibitors (afatinib and dacomitinib) and to third-generation inhibitors, currently 
represented by osimertinib; while the original indication for this drug was limited 
to the treatment of patients whose tumor had progressed during treatment with 
earlier-generation EGFR inhibitors by developing an acquired EGFR mutation in 
exon 20, known as T790M, osimertinib has recently been approved for the upfront 
treatment of patients harboring activating EGFR mutations, with a significant 
impact on the therapeutic algorithm of this specific population [12]. With regards 
to ALK rearrangements, several inhibitors have become available in clinical 
practice, their forerunner being represented by crizotinib, which achieved 
improved outcomes over first and second-line chemotherapy in populations of 
patients with ALK-rearranged NSCLC. Currently, the new ALK-inhibitor alectinib 
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has achieved improved progression-free survival (PFS) over crizotinib in first-
line, thus becoming the new standard for treatment-naïve ALK-rearranged 
NSCLC. Finally, with regards to advanced NSCLC harboring ROS1 
rearrangements, crizotinib represents the current agent of choice for first-line 
treatment [13]. 
THE ROLE OF IMMUNE CHECKPOINT INHIBITORS IN NSCLC 
The notion that neoplastic cells progressively acquire the ability to escape the 
surveillance of cells belonging to the immune system is well established; indeed, 
immuno-editing is known as the dynamic process leading to the development of 
immune-resistant neoplastic clones and is represented by three phases: 1) 
elimination (when innate and adaptive immune response engage tumor cells); 2) 
equilibrium (when non-immunogenic tumor cells have been selected and start 
growing); 3) escape (when tumor cells grow uncontrolled by the immune system, 
potentially developing cancer) [ 14 ]. The knowledge of this mechanism has 
encouraged studies with the aim of improving anti-neoplastic response from 
immune cells, and has led to various experimental therapeutic approaches, such as 
cancer vaccines. 
Immune checkpoints are crucial mechanisms of self-tolerance, developed to 
prevent autoimmune reactions. The most widely known actors of immune 
checkpoints are represented by cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4), which is expressed on activated T-cells and exerts its inhibitory 
function by binding CD-80 and CD-86 on the surface of antigen-presenting cells, 
and by the axis involving the programmed death protein 1 (PD-1) expressed on T-
cells, and its ligand (PD-L1), expressed on tumor cells. Since the pathways 
involving CTLA-4 and PD-1/PD-L1 are both associated with decreased T-cell 
activity, it has been postulated that the blockade of such signals could disrupt 
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immune tolerance, with subsequent antineoplastic effects. Furthermore, it has 
been observed that the expression of PD-L1, which is infrequent in normal tissue, 
might be up-regulated on tumor cell surface and hence play a relevant role in 
immune escape mechanisms; this notion has led to extensive investigation 
designed to define the role of PD-L1 expression as a clinically meaningful 
biomarker, as reported below. [15]. 
The first clinical model for immune checkpoint inhibition is represented by 
CTLA-4 blockade in metastatic melanoma, a malignancy well known for its 
immunogenicity, through the use of ipilimumab, a fully human IgG monoclonal 
antibody directed against CTLA-4 [16]. Subsequently, different agents designed 
to disrupt the PD-1/PD-L1 axis were developed in the same setting (metastatic 
melanoma), achieving superior outcomes even over ipilimumab, and hence 
becoming a standard of care for the management of metastatic melanoma [17]. 
While lung cancer had not previously been considered an immunogenic neoplasm, 
subsequent pre-clinical experiences suggested the contrary. While the studies 
involving immuno-modulation in NSCLC in the form of cancer vaccines led to 
underwhelming results [ 18 ], the first trial involving the CTLA-4 inhibitor 
ipilimumab in association with platinum-based chemotherapy as first-line for 
advanced NSCLC resulted in a significant advantage in terms of PFS over 
chemotherapy alone [19]. Subsequently, nivolumab, a fully human monoclonal 
antibody directed against PD-1, was compared to docetaxel as therapy for patients 
who had previously been treated with platinum-based chemotherapy for advanced 
NSCLC in two distinct randomized, phase III trials: Checkmate 017 (squamous 
histology), and Checkmate 057 (non-squamous histology). Both trials showed a 
statistically significant advantage in terms of median overall survival (OS) for 
nivolumab over docetaxel (9.2 vs. 6.0 months in Checkmate 017 and 12.2 vs. 9.4 
months in Checkmate 057); furthermore, the survival advantage was maintained 
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after a 3-year follow-up, with a 3-year OS rate of 17% with nivolumab as 
compared to 8% with docetaxel in the pooled populations from both trials. 
[ 20 , 21 , 22 ]. Another PD-1 inhibitor, pembrolizumab, was compared with 
docetaxel in the same setting (pre-treated advanced NSCLC) in the randomized, 
phase III Keynote 010 trial; notably, two different doses of pembrolizumab were 
evaluated (2 mg/Kg and 10 mg/Kg), and a significant advantage in terms of OS 
was observed with both doses of pembrolizumab as compared with docetaxel 
[23]. Notably, while a positive expression of PD-L1 on tumor cell membrane 
assessed by immunohistochemistry (IHC) was not required for enrolment in 
Checkmate 017 or Checkmate 057 (and the role of TPS was evaluated post-hoc), a 
tumor proportion score (TPS) of at least 1% was required in order to be enrolled 
in Keynote 010. The expression of PD-L1 was not prognostic or predictive of 
benefit from nivolumab in Checkmate 017 (squamous histology), while a positive 
association between positive PD-L1 expression (cut-offs 5% and 10%) and OS 
was observed in Checkmate 057 (non-squamous histology). In Keynote 010, 
while the trial population was enriched for tumors expressing PD-L1, the 
investigators observed that higher expression levels were predictive of improved 
survival benefit, as the hazard ratio (HR) for death with pembrolizumab vs. 
docetaxel was 0.53 in the sub-group with PD-L1 ≥ 50% and 0.76 for PD-L1 
expression 1%-49% [24]. Finally, atezolizumab is another monoclonal antibody 
designed to disrupt the PD-1/PD-L1 axis, with the difference that its target is PD-
L1. This agent was compared to docetaxel in a similar setting (pre-treated 
advanced NSCLC), and achieved significantly longer survival over chemotherapy 
(median OS: 13.8 vs. 9.6 months), and the benefit was observed irrespective of 
histology and PD-L1 status (patients who were negative for PD-L1 expression 
were eligible) [25]. An updated analysis after 2 years of follow-up was consistent 
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with the primary analysis of clinical benefit, and a tolerable safety profile was 
observed in spite of prolonged exposition to the agent [26]. 
Based on the results achieved in pre-treated NSCLC, immune checkpoint 
inhibitors were the subjects of several first-line trials, involving them both as 
single-agents and as part of combination regimens. Checkmate 026 compared 
single-agent nivolumab with platinum-based chemotherapy in a population of 
patients affected by treatment-naïve advanced NSCLC with positive PD-L1 
expression; the trial failed to show an advantage in terms of outcomes with 
nivolumab (median PFS and OS with nivolumab and chemotherapy were 4.2 vs. 
5.9 months, and 14.4 vs. 13.2 months, respectively), and was hence considered 
negative [27]. The phase III, randomized Keynote 024 trial was designed to 
compare pembrolizumab and first-line platinum-based chemotherapy in a 
population of NSCLC patients selected for high expression of PD-L1 (≥ 50%), on 
the basis of previous clinical data with pembrolizumab. Contrarily to what 
observed in Checkmate 026, in this trial, the PD-1 inhibitor achieved a statistically 
significant advantage in terms of PFS (10.3 vs. 6.0 months) and OS (30.0 vs. 14.2 
months) over chemotherapy in this selected patients’ population; therefore, 
pembrolizumab was approved as single-agent in treatment-naïve patients affected 
by advanced NSCLC with high PD-L1 expression [28,29]. 
In addition to single-agent regimens, immune checkpoint inhibitors have been 
employed also as part of combination strategies, including multiple checkpoint 
inhibitors or associations of immunotherapy and chemotherapy. Checkmate 227 
was a randomized, phase III trial designed to compare ipilimumab plus nivolumab 
versus platinum-based chemotherapy; notably, while the patients were not 
selected for PD-L1 expression, the enrolled patients were stratified also on the 
base of tumor mutational burden (TMB), as previous studies suggested that TMB 
is associated with immunogenicity; hence, tumor harboring high TMB (at least 10 
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mutations / megabase) could be more likely to respond to immunotherapy. The 
checkpoint inhibitors combination achieved longer PFS over chemotherapy (7.2 
vs. 5.5 months) in patients with high TMB, irrespective of PD-L1 expression [30]. 
However, subsequent OS data showed that also patients with low TMB achieved 
superior outcomes with ipilimumab-nivolumab compared to chemotherapy, thus 
questioning the role of TMB as a potential biomarker of benefit from 
immunotherapy [ 31 ]. A different phase III trial, Keynote 189, compared 
pembrolizumab versus placebo in combination with platinum-pemetrexed regimen 
in non-squamous advanced NSCLC. The combination of chemotherapy plus 
pembrolizumab achieved superior outcomes in terms of both PFS and OS over 
chemotherapy plus placebo (the median PFS was 8.8 vs. 4.9 months, while the 
median OS was not reached in the combination arm and it was 11.3 months in the 
placebo arm). Notably, the survival advantage was observed regardless of the 
level of PD-L1 expression [ 32 ]. A similar trial, Keynote 407, compared 
pembrolizumab versus placebo in combination with chemotherapy based on 
carboplatin plus paclitaxel/nab-paclitaxel in a population of patients affected by 
squamous advanced NSCLC. In this study, the addition of pembrolizumab 
resulted in significantly longer PFS and OS (6.4 vs. 4.8 months and 15.9 vs. 11.3 
months, respectively); similarly to Keynote 189, the survival advantage was 
consistent regardless of the expression of PD-L1 [33]. Finally, several trials 
explored the role of the addition of atezolizumab to different chemotherapy 
regimens, such as carboplatin plus paclitaxel, carboplatin plus nab-paclitaxel, or 
platinum plus pemetrexed. The most relevant of such trials is IMpower 150, 
which explored the effect of the addition of atezolizumab to carboplatin-paclitaxel 
+/- bevacizumab. In this study, the addition of atezolizumab to a regimen 
containing bevacizumab plus carboplatin-paclitaxel resulted in longer PFS (8.3 vs. 
6.8 months) and OS (19.2 vs. 14.7 months), and the benefit was consistent 
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regardless of PD-L1 expression; notably, the benefit was also observed in patients 
with liver metastases or with molecular alterations involving EGFR or ALK, 
which are typically clinical factors for poor response to immune checkpoint 
inhibition [34]. 
NOVEL PREDICTIVE BIOMARKERS FOR IMMUNOTHERAPY IN 
PREVIOUSLY TREATED NSCLC 
As reported, the expression of PD-L1 alone has a limited role in selecting which 
patients should receive immune checkpoint inhibitors or chemotherapy in second 
or subsequent lines of treatment for NSCLC. In first place, it has been observed 
that different assays yield discordant results; additionally, PD-L1 has been 
recognized to have a heterogeneous expression, associated to variable and not 
completely understood immune mechanisms [35,36,37]. Thus, identifying other 
potential biomarkers would result in improved patient selection for treatment with 
immune checkpoint inhibitors. 
According to preclinical studies, the cross-talk during immune response to cancer 
is not limited to PD-1/PD-L1 axis, and involves different molecules, either acting 
as co-stimulators or as immune checkpoints. For instance, PD-L2 binds PD-1 with 
inhibitory function, similarly to PD-L1; however, while PD-L1 is expressed in 
many cell lines, PD-L2 has a more restricted expression pattern, limited to 
dendritic cells, macrophages, and mast cells. Furthermore, PD-L2 might be 
associated with immune tolerance to normal respiratory cells [38 ,39]. Other 
molecules, such as B7-H3 and B7-H4, have been acknowledged as potential 
regulators of immunity and as prognostic factors in solid tumors [40]. B7-H3 has 
a controversial role in T cell response [41,42,43,44], and its expression on tumor 
cells is reportedly associated with poor prognosis in NSCLC [45,46]. B7-H4 is a 
trans-membrane protein suggested to inhibit the activation and the clonal 
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expansion of CD4+ and CD8+ cells, as well as the production of immune-
promoting cytokines; notably, the receptor of B7-H4 on immune cells has not 
been identified yet [47,48]. High expression of B7-H4 has been associated with 
poor prognosis in different solid tumors, including NSCLC [49,50,51,52]. 
While the aforementioned biomarkers seem to have a role in the modulation of 
immune response and prognostic significance in solid tumors, including NSCLC, 
their role in predicting response to immune checkpoint inhibitors has to be 
clarified yet; hence, our aim was to assess the association between the expression 
of these biomarkers and benefit from nivolumab in advanced NSCLC.  
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AIM OF THE PRESENT STUDY 
Our study explores the potential correlations between intra-tumor expression of a 
panel of immune-related biomarkers (PD-L2, PD-1, B7-H3, and B7-H4) and 
clinical outcomes of advanced NSCLC patients treated with nivolumab for 
advanced NSCLC (Nivolumab Cohort).  In order to define whether any 
meaningful biomarker identified in the Nivolumab Cohort might have a role in 
predicting the efficacy of immunotherapy, rather than a plain prognostic role, we 
retrospectively assessed the correlations between these biomarkers and outcomes 
of a population of patients who had been treated with platinum-based 
chemotherapy and had not subsequently received any immune checkpoint 
inhibitor (Chemotherapy Cohort). 
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MATERIALS AND METHODS 
NIVOLUMAB COHORT 
The Nivolumab Cohort included 46 patients affected by advanced NSCLC treated 
within the Italian Nivolumab Expanded Access Program (NCT02475382) and 
enrolled in a mono-institutional translational research study approved by our 
Local Ethics Committee (registry number: P.R. 191REG2015) [ 53 , 54 ]. The 
patients were eligible if they met the following criteria: i) cytologically or 
histologically confirmed advanced/metastatic NSCLC, ii) progression after at least 
one line of platinum-based chemotherapy, iii) Eastern Cooperative Oncology 
Group Performance Status (ECOG-PS)= 0-2, iv) no previous treatment with 
immune checkpoint inhibitors, iv) any brain metastasis had to be treated and 
clinically stable for at least 14 days before starting nivolumab, v) no treatment 
with corticosteroids at a dose higher than 10 mg/day of prednisone or equivalent. 
Eligible patients received nivolumab at 3 mg/kg every 14 days, with assessment 
by computed tomography scan (CT-scan) every 8 weeks. Nivolumab was 
administered until onset of unacceptable toxicities, patient's refusal, death or up to 
96 weeks from the start of treatment; treatment beyond tumor progression was 
allowed based on Investigators' judgment as long as clinical benefit was 
perceived. Objective responses and progression-free survival (PFS) were 
determined according to the Response Evaluation Criteria in Solid Tumors 
(RECIST) v.1.1; due to the peculiar mechanism of action of nivolumab, we 
assessed objective responses also with Immune-Related Response Criteria (irRC). 
Progression-free survival (PFS) and OS were calculated from the first 
administration of nivolumab to progression/death.  
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CHEMOTHERAPY COHORT 
The Chemotherapy Cohort included 27 treatment-naive patients with 
histologically or cytologically confirmed advanced non-squamous NSCLC and 
ECOG PS= 0-1 treated between 2011 and 2015 and drawn from a wider 
population of patients (n= 90) enrolled in a mono-institutional translational 
research study (NCT02055144) on the basis of available stored tissue for 
biomarker analyses. The regimen of choice was cisplatin plus pemetrexed for up 
to 4 cycles, followed by maintenance with pemetrexed. Carboplatin was 
administered in place of cisplatin to patients with a creatinine clearance < 60 
ml/min). Tumor response was assessed with RECIST v.1.1 every 2 cycles. 
Chemotherapy was administered until unacceptable toxicity, patient’s refusal, 
progression, or death. The aforementioned translational research study admitted 
patients with both squamous and non-squamous histology; however, to date, only 
the population affected by non-squamous histology completed accrual and was 
hence available for this analysis [55,56].  
IMMUNOHISTOCHEMISTRY (IHC) 
Sections of formalin-fixed, paraffin embedded (FFPE) tissue were cut at 2 µm and 
mounted on positively charged, adhesive glass slides (Superfrost Plus Gold, 
Thermo Scientific, Braunschweig, Germany). The IHC was carried out manually, 
miming the automated staining steps performed by Dako Autostainer Link 48, as 
indicated by the approved FDA protocol (PMA P150025; validated automated 
assay with rabbit monoclonal anti Human PD-L1 antibody clone 28-8 Pharm DX 
Dako). The sections were heated at 60°C for 15 minutes and washed with xylene 
(2 x 10 minutes) and ethanol (2 x 10 minutes) to remove paraffin. Antigen 
retrieval and primary antibody incubation were carried out at room temperature in 
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a hydrate chamber. Two sections of human placenta were included in each run as 
control; one section was incubated with the primary antibody containing the PD-
L1 rabbit monoclonal antibody, while a second section was incubated with the 
negative control reagent of the kit, an IgG rabbit monoclonal antibody in a buffer 
solution. A two-step immunoperoxidase staining method was used for all the 
antibodies (Dako EnVision + Dual Link System – HRP – DAB+) as follows: B7-
H4 (mouse monoclonal, clone MIH43, Abcam - dilution 1:60), B7-H3 (rabbit 
polyclonal, NovusBio - dilution 1:25), PD-L2 (mouse monoclonal, clone 8G8, 
LSBio - dilution 1:50), and PD-1 (rabbit polyclonal, Abcam - dilution 1:50). Each 
run contained a positive control (on-slide tonsil tissue for PD-1 and PD-L2, 
prostate cancer for B7-H3; breast carcinoma for B7-H4) and a negative control 
(no primary antibody). The 22C3 antibody was obtained from the commercially 
available PD-L1 PharmDX kit on the BenchmarkULTRA (Ventana Medical 
Systems/Roche, Tucson, AZ) platform, using the UltraView detection kit [57]. 
IHC SCORING 
The percentage of stained positive tumor cells was evaluated for each sample 
under light microscope by two pathologists; positive staining was defined as 
complete or partial circumferential membrane staining at any intensity or diffuse 
cytoplasmic staining.  
STATISTICAL ANALYSIS 
In Nivolumab Cohort, response categories according to RECIST v.1.1 and irRC 
were compared with the expression of each biomarker under study with Fisher's 
test or Chi Square test, as appropriate. Survival curves were compared between 
patient subgroups based on each biomarker expression by using Kaplan-Meier 
estimator. Cox’s Proportional Hazard Model was used for multivariate survival 
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analyses, starting from a model that included clinical and pathological 
characteristics, as well as the expression of the immune-related biomarkers. The 
final model was reached at by means of a stepwise regression with backward 
elimination of variables not significantly associated with PFS or OS, respectively, 
based on the Likelihood Ratio test. The same analyses were then repeated in the 
Chemotherapy Cohort, the rationale being that any difference between the 2 
cohorts in the prognostic role of a specific biomarker would suggest an 
association between the expression of said biomarker and the efficacy of 
immunotherapy. Due to the exploratory aims of these analyses, only Odds Ratio 
for objective response and HR for PFS and OS for each of the 5 biomarkers in the 
2 cohorts are reported, with their 95% CI, and no formal statistical comparison 






The Nivolumab Cohort included 46 evaluable patients, whose clinical 
characteristics are summarized in Table 1. PD-L1 and PD-1 were not evaluable in 
one and two samples, respectively, due to excessive background. B7-H4, PD-1 
and PD-L2 stainings were observed in cytoplasm, while B7-H3 was detected in 
both cell membrane and cytoplasm and PD-L1 was exclusively expressed in cell 
membrane. Representative images of IHC staining of PDL-1 and B7-H4 are 
reported  in Figure 1, while the expression of each immune-related parameter is 
reported in Table 2 and in Supplementary Table 1. All the biomarkers apart 
from PD-1 showed an expression < 1% in most samples; consistently with the cut-
off values of previous studies involving immune checkpoint inhibitors in pre-
treated NSCLC patients [58,59,60], we selected the value of 1% as an appropriate 
cuf-off for defining positive (≥ 1%) vs. negative (< 1%) samples for each potential 
biomarker. No significant correlations were observed among the expressions of 
the biomarkers. 
When clinical characteristics were compared with each biomarker, PD-L2 
expression was associated with ECOG PS= 0 (p-value= 0.038), while PD-1 
expression was associated with age ≥70 years (p-value= 0.026) and B7-H3 
expression was associated with squamous histology (p-value= 0.023).  
No statistically significant association between the expression of the immune-
related biomarkers and the proportion of ORR and DCR was observed, although, 
notably, none of the six patients expressing B7-H3 achieved objective response. 
Progression-free survival was evaluable for 44 out of 46 patients according to 
RECIST. One patient discontinued treatment before the first assessment and did 
not undergo further CT scans after baseline; another patient had non-measurable 
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disease according to RECIST, but was considered evaluable by irRC, as the 
baseline lesions met the requirements for measurability with such criteria. Seven 
patients died before undergoing the first response evaluation. The overall outcome 
data are reported in Supplementary Table 2. With regards to univariate PFS 
analysis, B7-H3 expression was associated with significantly lower RECIST-PFS 
(median PFS 1.6 vs. 2.0 months; p-value= 0.009); while this result should be 
considered with caution due to the fact that only six out of 44 patients expressed 
B7-H3, the rapid progression of all these patients was noteworthy. More 
importantly, B7-H4 expression was associated with significantly reduced 
RECIST-PFS (median 1.7 vs. 2.0 months; p-value= 0.026); no other biomarker 
was associated with differences in terms of RECIST-PFS. The irRC-PFS analyses 
based on each immune-related biomarker were generally consistent with RECIST-
PFS analyses, although the irRC-PFS difference based on B7-H3 expression fell 
short of statistical significance (p-value= 0.057). In the multivariate RECIST-PFS 
analysis, the only variables significantly associated with shorter PFS were B7-H3 
expression (HR= 4.14; 95% CI: 1.44-11.9; p-value= 0.019) and B7-H4 expression 
(HR= 2.28; 95% CI= 1.16-4.48; p-value= 0.021). The multivariate irRC-PFS 
analysis was consistent with the RECIST-PFS analysis. 
In the univariate OS analyses, no significant association with immune-related 
biomarkers was observed, although the association between B7-H4 expression 
and reduced OS was close to significance (4.37 vs. 9.83 months; p-value= 0.064). 
In multivariate analysis, OS was significantly reduced in patients with ECOG-PS= 
1-2 vs. PS= 0, (HR= 2.73; 95% CI= 1.21-6.15; p-value= 0.01) and in patients with 
B7-H4 expression (HR= 2.38; 95% CI= 1.16-4.91; p-value= 0.022). A weak, non-
significant association between PD-L1 expression and OS was observed (HR = 
0.60; 95% CI= 0.15 -2.37 p-value= 0.460).  
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The Kaplan-Meier curves for RECIST-PFS and OS according to the expression of 
B7-H4 and the other biomarkers are reported in Figures 2-3, and in 
Supplementary Figures 5-17, respectively. 
VALIDATION OF PD-L1 IHC IN THE NIVOLUMAB COHORT 
We have noticed that our proportion of patients expressing PD-L1 determined by 
using our manual staining based on the 28-8 clone was low (15.21%), compared 
to what has been reported in other studies, ranging from 20% to over 50% [61]. 
Hence, in order to validate our proportion of PD-L1-expressing patients, we 
subsequently performed an automated staining; since the automated staining 
available within our Institution is based on the 22C3 pharmDx assay, which has 
been approved as a companion diagnostic assay for the use of pembrolizumab in 
NSCLC [62], we used this clone, hence being also able to compare the two clones 
in our population. Globally, 34 specimens had sufficient neoplastic areas for this 
additional analysis; 31 specimens (91.18%) had the same PD-L1 expression level 
with 28-8 and 22C3 assays. Among the three discordant samples, two resulted 
<1% with the 22C3 assay, while the 28-8 assay identified an expression between 
1-9%; by contrast, one sample was categorized as ≥50% according to the 22C3 
assay and between 10-49% according to the 28-8 assay. When the two assays 
were compared using the cut-off of 1% for positivity, a substantial concordance 
was observed (Cohen’s Kappa= 0.767) 
CHEMOTHERAPY COHORT 
Tumor samples from 27 NSCLC patients within the Chemotherapy Cohort were 
collected. Since the available tissue was limited, we focused this analysis on B7-
H4 and PD-L1 on the basis of the results concerning OS observed in the 
Nivolumab Cohort. The patients’ characteristics are summarized in Table 1, while 
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the expressions of PD-L1 and B7-H4 are reported in Table 2 and in 
Supplementary Table 3. We applied the same cut-off for positivity already 
employed in the Nivolumab Cohort (≥ 1% vs. < 1%). No correlation was observed 
between PD-L1 and B7-H4 expression. PD-L1 positivity was not associated with 
any clinical feature, while B7-H4 expression was associated with female gender 
(p-value= 0.008). The global outcome data for the Chemotherapy Cohort are 
reported in Supplementary Table 4. No significant correlation was observed 
between the expression of any biomarker and ORR or DCR, as reported in 
Supplementary Figures 18-19. No association between biomarker expression 
and survival was observed: in particular, at the univariate analysis, patients with 
B7-H4 expression ≥ 1% vs. < 1% had similar median RECIST-PFS (3.3 vs. 3.4 
months; p-value= 0.274) and OS (8.7 vs. 8.2 months; p-value= 0.284); similarly, 
PD-L1 expression did not significantly affect neither RECIST-PFS (4.8 vs. 3.3 
months; p-value= 0.444), nor OS (12.8 vs. 7.4 months; p-value= 0.406). At the 
multivariate analysis, RECIST-PFS was not associated with B7-H4 expression 
(HR= 0.64; 95% CI= 0.29-1.44; p-value= 0.275) or PD-L1 expression (HR= 0.74; 
95% CI= 0.29-1.90; p-value= 0.446); likewise, OS was not associated with B7-H4 
expression (HR= 0.85; 95% CI= 0.36-2.03; p-value= 0.287) or PD-L1 expression 
(HR= 0.50; 95% CI= 0.18-1.38; p-value= 0.408). 
The Kaplan-Meier curves of PFS and OS based on B7-H4 expression are reported 
in figure 4, while those based on PD-L1 expression are reported in 




Our study focused on a panel of potential immune-related biomarkers with the 
aim of identifying possible correlations with the oucomes of a population of 
patients receiving nivolumab for advanced NSCLC. Interestingly, meaningful 
correlations were found between the expression of B7-H4 and survival of patients 
reeiving nivolumab. Notably, while the association between B7-H4 and OS did 
not reach statistical significance, (p= 0.064), 10 patients who had B7-H4 
expression <1% were alive, hence censored at the time of our analysis, compared 
to only 2 patients in the B7-H4-positive group, supporting the observation of a 
difference between the two sub-populations. Furthermore, no difference in terms 
of PFS or OS was observed when B7-H4 expression was assessed in a cohort of 
patients receiving chemotherapy for advanced NSCLC.  
While the clinical meaning of B7-H4 in NSCLC has been considered debatable 
for many years, a recent meta-analysis comprising 9 studies, for a total of 1444 
patients with NSCLC at any stage, demonstrated a correlation between B7-H4 
expression and clinicopathological features such as poor differentiation, advanced 
disease stage and poor survival, suggesting a prognostic role of this biomarker. 
However, this meta-analysis has some limitations, deriving from possible patient 
selection biases and from the fact that only the results of few studies were 
evaluable for survival analysis [63]; furthermore, the nature of a meta-analysis 
including all stages of NSCLC limits the available information on the effects of 
B7-H4 on specific treatments. Our experience, while developed within a mono-
institutional study, suggests that the role of B7-H4 in advanced NSCLC might 
depend on the administered treatment, with particular reference to 
immunotherapy. We acknowledge that the two populations of our study differ as 
Nivolumab Cohort included patients with both histo-types (squamous and non-
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squamous NSCLC) and who had received previous antineoplastic treatments for 
advanced disease, while Chemotherapy Cohort included only patients with 
adenocarcinoma receiving first-line chemotherapy, thus limiting formal statistical 
comparisons between the two cohorts. However, the clearly different behaviour of 
B7-H4 in the two cohorts is noticeable. PD-L1 and B7-H4 seem to have opposite 
effect in our population of patients receiving nivolumab and they are both known 
to promote immune tolerance, and subsequently the ability of tumor cells to 
escape the immune system; more specifically, while the immuno-regulatory role 
of PD-1/PD-L1 axis is widely known [ 64 ], B7-H4 appears to inhibit the 
proliferation of T-killer and T-helpers and to favor the proliferation of regulatory 
T cells (Tregs) with inhibitory function in different malignancies, although its 
receptor has not been identified yet [65 ,66 ]. While available information is 
currently limited, on the basis of our findings and previous publications we might 
speculate that, while PD-L1 expression has a favoring effect on the treatment with 
PD-1/PD-L1 immune checkpoint inhibitors, B7-H4 expression might promote 
immune tolerance through a completely different pathway, hence favoring 
immune tumor escape in spite of PD-1/PD-L1 blockade. 
While our findings are mostly focused on B7-H4 and PD-L1, no meaningful result 
involving PD-L2 and PD-1 was observed. Notably, although B7-H3 expression 
brought interesting results in terms of decreased PFS within our Nivolumab 
Cohort, in line with other publications [ 67 ], the number of B7-H3-positive 
patients was globally low; therefore the conclusions we could draw about this 
biomarker in our experience were limited and require further assessments in this 
setting. 
We are aware that our study has some limitations, mostly deriving from its nature 
of being a mono-institutional, retrospective study based on two different cohorts 
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of patients affected by advanced NSCLC. In first place, there are clinically 
meaningful differences in the cohorts, resulting in a limitation to the available 
aggregate analyses; howerer, the mono-institutional approach ensured that all the 
clinical assessments, including ORR and PFS data collection, were performed 
consistently among all the patients, and the same concept applies to IHC staining 
and analysis. In second place, the global number of patients is relatively limited, 
especially for Chemotherapy Cohort; this occurrence is related to the limited 
amount of available specimens which were suitable for IHC, since different 
biomarkers had to be explored in Nivolumab Cohort, while in the case of 
Chemotherapy Cohort we must take into account that, since these patients were 
enrolled in a translational research study, their samples had undergone multiple 
different analyses in the course of time, both for clinical reasons and for research 
purpose, thus reducing the number of specimens that could be properly analyzed 
for PD-L1 and B7-H4 expression. Notably, this issue also affects current clinical 
practice in NSCLC, as collecting the proper amount of tissue is still a challenging 
medical need. Furthermore, the analysis was mostly performed on archival 
samples, but this also reflects the current practice in NSCLC, as the collection of 
repeated biopsies is not mandatory for first-line chemotherapy or for the 
administration of nivolumab in subsequent lines. 
With regards to IHC, although the employment of manual technique may be  
considered a limit for our study, we have adapted the kit provided by DAKO 
company to meet laboratory requirements by developing a protocol that simulates 
the steps taken on the recommended platform for the development of the 
immunohistochemistry reaction; additionally, every staining run was supported by 
proper positive and negative controls and a careful interpretation of results, 
resulting in the exclusion the samples which were not adequate for our analysis. 
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Furthermore, while we have observed a lower proportion od PD-L1-positive 
patients compared to other publications, the automated validation performed by 
using the 22C3 assay substantially confirmed our findings, and was substantially 
concordant with our initial assessment, with only three reported discordant cases, 
two of which switched from border-line negativity (<1%) to bordel-line positivity 
(≥1%) and one of which being positive with both assays (10-49% with 28-8 and 
≥50% with 22C3). A possible explanation for our low proportion of PD-L1 ≥1% 
specimens compared to other publications may lie in the intra-tumoral 
heterogeneity of PD-L1 expression, especially when we consider the tissue 
collected through biopsies, rather than surgical specimens [68,69]. 
In conclusion, to our knowedge, this is the first clinical study suggesting a 
potential role of B7-H4 expression as predictor of benefit from PD-1 blockade 
with nivolumab in NSCLC; while limited due to the nature of the study and the 
number of evaluable patients, our findings strongly encourage future prospective 
studies designed to define and eventually confirm the predictive role of B7-H4 






Figure 1. Representative images of IHC positive controls (A-B) and tumor 
samples from the Nivolumab Cohort (C-L). A: positive PD-L1 control (placenta); 
B: positive B7-H4 control (breast carcinoma); C-D: EE and IHC positive staining 
of PD-L1; E-F: EE and IHC positive staining of B7-H4; G-H: EE and IHC 
negative staining of PD-L1; I-L: EE and IHC negative staining of B7-H4. All the 









Figure 2. Kaplan-Meier curve for RECIST-PFS based on the expression of 
B7-H4 defined as ≥ 1% vs. < 1% in the Nivolumab Cohort. 
 
 Figure 3. Kaplan-Meier curve for OS based on the expression of B7-H4 
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N° at risk 
≥1 17 11 8 6 3 1 1 0 





Figure 4. Kaplan-Meier curves for RECIST-PFS (A) and OS (B) based on 
























N° at risk 
≥1 15 9 6 5 3 3 1 0 































N° at risk 
≥1 15 13 9 7 5 5 4 2 2 






Table 1. Clinical and molecular characteristics of the evaluable patients in the 
Nivolumab Cohort and in the Chemotherapy Cohort. 
1 Total = 99.99% due to approximation. 
2 The Chemotherapy Cohort includes only chemotherapy-naïve patients affected 
by non-squamous NSCLC with ECOG PS= 0-1. 
3 Two patients in the Nivolumab Cohort had exon 19 deletion; one patient had 
exon 19 deletion in association with exon 20 insertion. 
4 One patient in the Chemotherapy Cohort had exon 21 deletion, which was 







Table 2. Expression of the potential immune-related biomarkers in the Nivolumab 
Cohort and in the Chemotherapy Cohort reported into each cut-off category; the 
evaluable samples from each cohort were then divided between positive (≥ 1%) 
and negative (< 1%) expression. 
ND: Not determined. 
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Supplementary Table 1: Distribution of the biomarker expressions among the 
samples collected from each patient within the Nivolumab Cohort. ND: not 
determined. 
 
PATIENT PD-L1 PD-L2 PD-1 B7-H3 B7-H4 
1 <1% 10%-49% <1% <1% <1% 
2 <1% <1% 1%-9% <1% 1%-9% 
3 <1% <1% 1%-9% <1% ≥50% 
4 <1% <1% 10%-49% <1% <1% 
5 <1% <1% ≥50% <1% <1% 
6 <1% <1% ≥50% 10%-49% ≥50% 
7 <1% <1% ≥50% <1% ≥50% 
8 <1% <1% <1% <1% <1% 
9 <1% <1% <1% 10%-49% <1% 
10 <1% <1% <1% <1% <1% 
11 1-9% <1% 1%-9% <1% 1%-9% 
12 <1% <1% ≥50% 1%-9% <1% 
13 <1% <1% <1% <1% <1% 
14 <1% <1% 1%-9% <1% <1% 
15 <1% <1% ≥50% <1% <1% 
16 ≥50% <1% ≥50% <1% ≥50% 
17 <1% <1% 10%-49% <1% ≥50% 
18 <1% <1% ≥50% <1% 10%-49% 
19 <1% <1% ≥50% <1% <1% 
20 <1% <1% ND ≥50% 1%-9% 
21 <1% <1% 10%-49% 10%-49% 10%-49% 
22 <1% <1% 1%-9% <1% ≥50% 
23 <1% 1%-9% 10%-49% <1% <1% 
24 <1% <1% <1% <1% <1% 
25 <1% 10%-49% <1% <1% <1% 
26 1%-9% <1% ≥50% <1% <1% 
27 10%-49% 10%-49% ≥50% <1% 10%-49% 
28 <1% <1% <1% <1% <1% 
29 <1% <1% ≥50% <1% <1% 
30 <1% <1% ≥50% <1% <1% 
31 1%-9% <1% ≥50% <1% <1% 
32 <1% <1% <1% <1% <1% 
33 <1% <1% <1% <1% ≥50% 
34 <1% <1% 1%-9% <1% <1% 
35 <1% <1% 1%-9% <1% <1% 
36 1%-9% <1% >=50% <1% <1% 
37 <1% 1%-9% 1%-9% <1% <1% 
38 <1% 10%-49% <1% <1% <1% 
39 10%-49% <1% 10%-49% <1% ≥50% 
40 <1% <1% ND <1% <1% 
41 <1% <1% <1% 1%-9% 1%-9% 
42 ND <1% ≥50% <1% <1% 
43 <1% <1% ≥50% <1% 1%-9% 
44 <1% <1% <1% <1% <1% 
45 <1% ≥50% ≥50% <1% <1% 
46 <1% 10%-49% ≥50% <1% 10%-49% 
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Supplementary table 2: global outcome data in the Nivolumab Cohort. 
Among the patients from the Nivolumab Cohort, one was considered 
evaluable for irRC, but not for RECIST, based on measurable lesions; one 
additional patient was considered not evaluable as he/she discontinued 
treatment and did not undergo further CT scans after baseline; both 
patients were followed for overall survival. 
Among the patients who were evaluable for PFS, one missed the first 
scheduled response assessment although subsequent scans were 





Nivolumab Cohort N= 46 
Median OS (95% IC) 8.9 months (4.4-12.2) 
Evaluable patients for PFS RECIST irRC N= 44 N= 45 






ORR RECIST irRC 14.0% 13.6% 





Supplementary figure 1: RECIST-ORR according to biomarkers 
expression at IHC in the Nivolumab Cohort. No statistically significant 
interaction was observed between each biomarker and ORR, although the 
correlation between PD-L2 expression and RECIST-ORR was close to 






Supplementary figure 2: RECIST-DCR according to biomarkers 
expression at IHC in the Nivolumab Cohort. No statistically significant 
interaction was observed between each biomarker and DCR, although the 
correlation between B7-H4 expression and RECIST-DCR was close to 



















































Supplementary figure 3: irRC-ORR according to biomarkers expression 
at IHC in the Nivolumab Cohort. No statistically significant interaction was 






Supplementary figure 4: irRC-DCR according to biomarkers expression 
at IHC in the Nivolumab Cohort. No significant interaction was observed 


















































Supplementary figure 5: RECIST-PFS based on the expression of PD-L1 

























N° at risk 
≥1 6 2 2 1 1 0 






Supplementary figure 6: irRC-PFS based on the expression of PD-L1 

























N° at risk 
≥1 7 3 2 1 0 





Supplementary figure 7: OS based on the expression of PD-L1 defined 































N° at risk 
≥1 7 5 5 5 2 2 1 0 





Supplementary figure 8: RECIST-PFS based on the expression of PD-L2 


























N° at risk 
≥1 8 4 4 2 2 2 2 0 





Supplementary figure 9: irRC-PFS based on the expression of PD-L2 


























N° at risk 
≥1 8 4 3 2 1 1 1 0 





Supplementary figure 10: OS based on the expression of PD-L2 defined 


































N° at risk 
≥1 8 8 7 5 2 2 1 1 0 





Supplementary figure 11: RECIST-PFS based on the expression of PD-1 


























N° at risk 
≥1 30 7 4 1 1 0 





Supplementary figure 12: irRC-PFS based on the expression of PD-1 


























N° at risk 
≥1 31 11 7 4 2 2 1 0 





Supplementary figure 13: OS based on the expression of PD-1 defined 


































N° at risk 
≥1 31 24 18 16 9 6 2 0 





Supplementary figure 14: RECIST-PFS based on the expression of B7-


























N° at risk 
≥1 6 0 





Supplementary figure 15: irRC-PFS based on the expression of B7-H3 


























N° at risk 
≥1 6 1 1 0 





Supplementary figure 16: OS based on the expression of B7-H3 defined 


































N° at risk 
≥1 6 5 2 2 1 0 




Supplementary figure 17: irRC-PFS based on the expression of B7-H4 
























N° at risk 
≥1 17 4 2 0 













Supplementary Table 3: Distribution of the biomarker expressions among the 
samples collected from each patient within the Chemotherapy Cohort.  
 
 
PATIENT PD-L1 B7-H4 
1 <1% 10%-49% 
2 <1% ≥50% 
3 <1% ≥50% 
4 <1% ≥50% 
5 1%-9% 1%-9% 
6 <1% <1% 
7 <1% <1% 
8 <1% <1% 
9 <1% 1%-9% 
10 <1% ≥50% 
11 <1% ≥50% 
12 <1% <1% 
13 10%-49% <1% 
14 1%-9% ≥50% 
15 <1% 10%-49% 
16 <1% ≥50% 
17 <1% <1% 
18 <1% 1%-9% 
19 <1% 10%-49% 
20 1%-9% <1% 
21 <1% <1% 
22 <1% ≥50% 
23 <1% <1% 
24 <1% <1% 
25 1%-9% ≥50% 
26 1%-9% <1% 











Chemotherapy Cohort N= 27 
Median OS (95% CI) 8.3 months (4.3-13.2) 
Evaluable patients for PFS N= 27 






Supplementary figure 18: RECIST-ORR according to biomarkers 
expression at IHC in the Chemotherapy Cohort. No significant interaction 







Supplementary figure 19: RECIST-DCR according to biomarkers 
expression at IHC in the Chemotherapy Cohort. No significant interaction 















































Supplementary figure 20: RECIST-PFS based on the expression of PD-


























N° at risk 
≥1 6 4 3 2 2 2 0 





Supplementary figure 21: OS based on the expression of PD-L1 defined 



































N° at risk 
≥1 6 6 5 3 3 3 1 1 1 
<1 21 17 11 9 6 5 4 1 1 
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